Achieve Life Sciences (ACHV)
(Delayed Data from NSDQ)
$4.58 USD
+0.04 (0.77%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.56 -0.02 (-0.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACHV 4.58 +0.04(0.77%)
Will ACHV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACHV based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ACHV
Jones starts Achieve Life Sciences at buy, cites market opportunity
Achieve Life Sciences: A Strong Buy for Tobacco Cessation Market Penetration
Achieve Life Sciences initiated with bullish view at JonesResearch, here's why
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
Analysts Offer Insights on Healthcare Companies: Forian (FORA), Achieve Life Sciences (ACHV) and P3 Health Partners (PIII)